Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UBR1

UPID:
BUP1_HUMAN

ALTERNATIVE NAMES:
BUP-1; Beta-alanine synthase; N-carbamoyl-beta-alanine amidohydrolase

ALTERNATIVE UPACC:
Q9UBR1; A3KMF8; Q9UIR3

BACKGROUND:
The enzyme Beta-ureidopropionase, identified by the accession number Q9UBR1, is integral to the catabolism of pyrimidine, converting specific substrates into beta-alanine, ammonia, and carbon dioxide. This process is essential for the maintenance of nitrogen balance within the human body.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Beta-ureidopropionase could open doors to potential therapeutic strategies. Its direct involvement in Beta-ureidopropionase deficiency highlights its importance in human health and disease, offering a promising target for drug discovery efforts aimed at correcting metabolic imbalances.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.